Pulse Biosciences (PLSE)
(Real Time Quote from BATS)
$17.24 USD
-0.09 (-0.52%)
Updated Oct 14, 2025 01:32 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PLSE 17.24 -0.09(-0.52%)
Will PLSE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PLSE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLSE
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Other News for PLSE
Is PLSE signaling a buying opportunity? 200 Day Moving Average Support shows up after dropping 1.53%
Fell Below 20 Day Moving Average appears for PLSE after 8.57% move
Pulse Biosciences Reveals Promising Study Results
PLSE's price falls by 3.46% on October 9, though its technical setup remains stable.
PLSE forms Pocket Pivot on October 8